Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Total revenues	$ 89,432	$ 102,215	$ 169,375	$ 170,945
Cost and expenses:
Cost of revenues		11,313	2,239	12,356
Research and development	22,076	28,758	50,103	60,956
Selling, general and administrative	34,643	43,246	71,093	92,341
Gain on lease modification		(3,169)		(3,169)
Restructuring expenses		490		3,818
Total cost and expenses	56,719	80,638	123,435	166,302
Income from operations	32,713	21,577	45,940	4,643
Other (expense) income:
Interest expense	(7,318)	(9,430)	(14,538)	(19,022)
Interest and investment income	276	668	1,053	1,404
(Loss) gain on derivatives	(467)	(672)	(3,933)	3,272
Other income		140	27	140
Other expense, net	(7,509)	(9,294)	(17,391)	(14,206)
Net income (loss) from continuing operations	25,204	12,283	28,549	(9,563)
Net loss from discontinued operations				(37,438)
Net income (loss)	25,204	12,283	28,549	(47,001)
Comprehensive income (loss)	$ 25,204	$ 12,283	$ 28,549	$ (47,001)
Net income (loss) per share from continuing operations-basic and diluted	$ 0.16	$ 0.08	$ 0.18	$ (0.06)
Net loss per share from discontinued operations - basic and diluted (in dollars per share)				(0.24)
Net income (loss) per share - basic and diluted (in dollars per share)	$ 0.16	$ 0.08	$ 0.18	$ (0.30)
Weighted average shares used in computing net income (loss) per share - basic:	159,407	155,849	158,890	155,405
Weighted average shares used in computing net income (loss) per share - diluted:	159,920	155,849	160,032	155,405
Collaborative arrangements revenue
Revenues:
Total revenues	$ 89,423	$ 77,322	$ 163,868	$ 143,474
Sale of active pharmaceutical ingredient
Revenues:
Total revenues	$ 9	$ 24,893	$ 5,507	$ 27,471